1. Home
  2. AOSL vs SGMT Comparison

AOSL vs SGMT Comparison

Compare AOSL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha and Omega Semiconductor Limited

AOSL

Alpha and Omega Semiconductor Limited

HOLD

Current Price

$24.76

Market Cap

793.5M

Sector

Technology

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$10.46

Market Cap

676.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AOSL
SGMT
Founded
2000
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
793.5M
676.3M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
AOSL
SGMT
Price
$24.76
$10.46
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$24.00
$26.13
AVG Volume (30 Days)
518.8K
1.0M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
57.27
N/A
EPS
N/A
N/A
Revenue
$342,291,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.01
$4.50
52 Week High
$54.34
$11.45

Technical Indicators

Market Signals
Indicator
AOSL
SGMT
Relative Strength Index (RSI) 37.60 61.77
Support Level $19.92 $6.60
Resistance Level $37.00 $11.15
Average True Range (ATR) 0.98 0.51
MACD 0.27 -0.08
Stochastic Oscillator 23.97 56.18

Price Performance

Historical Comparison
AOSL
SGMT

About AOSL Alpha and Omega Semiconductor Limited

Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: